Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual DiseaseBusiness Wire • 07/12/22
Personalis, Inc.'s (PSNL) CEO John West on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
Evaxion to Utilize Personalis' ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage MelanomaBusiness Wire • 04/26/22
Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic SalesBusiness Wire • 04/21/22
Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA GeneBusiness Wire • 04/12/22
Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ PlatformBusiness Wire • 04/12/22
Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022Business Wire • 04/11/22
Personalis to Present at the 21st Annual Needham Virtual Healthcare ConferenceBusiness Wire • 03/31/22
Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of DirectorsBusiness Wire • 03/24/22
Personalis to Present Data Demonstrating Breadth of NeXT Platform for Oncology at AACR Annual Meeting 2022Business Wire • 03/23/22
Personalis Inc's (PSNL) CEO John West on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/25/22
Earnings Preview: Personalis (PSNL) Q4 Earnings Expected to DeclineZacks Investment Research • 02/17/22
Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease DetectionBusiness Wire • 02/15/22
Personalis to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceBusiness Wire • 02/01/22
Personalis to Participate in the 24th Annual Needham Virtual Growth ConferenceBusiness Wire • 12/28/21